retatrutide clinical trial phase Eli Lilly's 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Today, we shared new data

All dosage information below comes from published clinical trial data

Dosing frequency depends on the specific GLP-1 prescribed: Once-daily injections (e } What to Expect After Starting GLP-1 Injections Its common for licensed providers to start patients at a lower dose, which may minimize side effects and build tolerance

Once you answer the few questions, click the get my plan button to fill out the intake form, which includes some brief notes about medical history (like what medications and supplements you take, how often you enjoy an adult beverage, etc.)

Phase 3 trials (the TRIUMPH programme, registered on ClinicalTrials.gov) are currently underway, evaluating retatrutide across broader populations including those with cardiovascular disease, type 2 diabetes, and obesity-related complications

This approach reduces the long-term side effect burden and cost of peptide therapy

The foundation's annual youth survey found that more than half of all young people aged 12-18 reported being dissatisfied with their bodies in 2024